Effectiveness of treatment of moderate ulcerative colitis with prolonged mesalazine in real clinical practice

Introduction. Ulcerative colitis (UC) is one of the severe therapeutic diseases. High doses of oral granular mesalazine are required to maintain clinical and endoscopic remission of UC, which may be sufficient and supposedly more acceptable for patients, as some studies showed that adherence to topi...

Full description

Bibliographic Details
Published in:	Медицинский совет
Main Authors:	O. V. Knyazev, A. V. Kagramanova, A. A. Lishchinskaya
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2021-10-01
Subjects:	inflammatory bowel diseases mesalazine with ethylcellulose coating 5-aminosalicylic acid prolonged mesalazine ulcerative colitis
Online Access:	https://www.med-sovet.pro/jour/article/view/6448

Similar Items

Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis
by: O. V. Knyazev, et al.
Published: (2021-05-01)

Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis
by: Yu. P. Uspenskiy, et al.
Published: (2022-03-01)

Comparative evaluation of the effectiveness of monotherapy of ulcerative colitis with mesalazine MMX and combination therapy with non-prolonged mesalazines with rectal forms
by: O. V. Knyazev, et al.
Published: (2022-08-01)

THE RESULTS OF THE USE OF 5-AMINOSALICYLIC ACID AS AN ANTI-RELAPSE AND MAINTENANCE THERAPY ULCERATIVE COLITIS MODERATE SEVERITY IN CLINICAL PRACTICE
by: O. V. Knyazev, et al.
Published: (2018-01-01)

Comparison of PUCAI Score in Mesalazine-Treated Children with Ulcerative Colitis
by: Nadia Chairunnisa, et al.
Published: (2023-05-01)

USE OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF ULCERATIVE COLITIS IN DIFFERENT DOSAGE MODES
by: M. V. Shapina, et al.
Published: (2017-11-01)

A Case Report and Literature Review of Mesalazine-Induced Kidney Injury in a Pediatric Patient With Ulcerative Colitis
by: Shuo Wang, et al.
Published: (2022-05-01)

Mesalazin-induced eosinophilic pneumonia in a 15-year-old boy with ulcerative colitis
by: G. N. Yankinа, et al.
Published: (2019-10-01)

SOME ASPECTS OF TREATMENT FOR LEFT-SIDED ULCERATIVE COLITIS
by: P. A. Makarchuk, et al.
Published: (2016-02-01)

Effective domestic mesalazine in the therapy of ulcerative colitis
by: I. N. Ruchkina, et al.
Published: (2021-06-01)

Investigating the effects of combined treatment of mesalazine with Lactobacillus casei in the experimental model of ulcerative colitis
by: Shabnam Bahrami, et al.
Published: (2024-10-01)

Drug-Induced Lung Disease (Organizing Pneumonia) Associated with Mesalazine
by: E. V. Smirnova, et al.
Published: (2022-02-01)

A Rare Case of Pyoderma Gangrenosum as a Complication of Ulcerative Colitis: A Case Report and Literature Review
by: Amin Shah, et al.
Published: (2025-10-01)

MESALAZINE PLACE IN THERAPY OF ULCERATIVE COLITIS
by: I. G. Bakulin, et al.
Published: (2017-11-01)

The impact of low-dose Fructooligosaccharide combined with Mesalazine on inflammation levels and therapeutic effects in elderly patients with ulcerative colitis
by: Wang Fangfang, et al.
Published: (2025-07-01)

4-aminosalicylic acid as a coupling reagent for spectrophotometric determination of mesalazine in an aqueous medium
by: Mohamed Y. Dhamra, et al.
Published: (2024-06-01)

A systematic review and meta-analysis of Danshen combined with mesalazine for the treatment of ulcerative colitis
by: Wei Zhang, et al.
Published: (2024-05-01)

Current Mesalazine Products: Differences in Enteric-Coated Dosage Forms and Pharmaceutical Risks of Clinical Efficacy Reduction (Review)
by: S. Yu. Serebrova, et al.
Published: (2024-12-01)

Clinical observation of probiotics combined with mesalazine and Yiyi Baitouweng Decoction retention enema in treating mild-to-moderate ulcerative colitis
by: Li Yanlong, et al.
Published: (2025-02-01)

Drugs for the treatment of ulcerative colitis on the pharmaceutical market of Ukraine
by: L. M. Palchak, et al.
Published: (2023-02-01)

Evaluation of the Anti-inflammatory Effect of Aqueous Extract of Pistacia atlantica Gum in an Experimental Model of Ulcerative Colitis
by: Shabnam Bahrami, et al.
Published: (2024-04-01)

Analysis of clinical characteristics of mesalazine-induced cardiotoxicity
by: Junyu Chen, et al.
Published: (2022-09-01)

A case of ulcerative colitis complicated by a simple appendiceal opening
by: Xiao Liu, et al.
Published: (2024-04-01)

Bickerstaff’s brainstem encephalitis: a rare case of neurologic complication in Ulcerative Colitis
by: Haram Joo, et al.
Published: (2023-10-01)

Efficacy and safety of tanshinone IIA in combination with mesalazine in the treatment of ulcerative colitis: a Systematic review and meta-analysis
by: Xiao Chen, et al.
Published: (2024-11-01)

Optimization of approaches to the treatment of mild to moderate ulcerative colitis
by: S. S. Belous, et al.
Published: (2021-09-01)

Effects of Yunnan Baiyao retention enema combined with mesalazine enteric-coated tablets and bifidobacterium triple viable capsules for treating ulcerative colitis
by: Liu Junjie, et al.
Published: (2022-04-01)

Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis
by: Kristine Paridaens, et al.
Published: (2023-07-01)

Medication Formulation Preference of Mild and Moderate Ulcerative Colitis Patients: a European Survey
by: Xavier Hébuterne, et al.
Published: (2023-05-01)

Mesalazine use tactics in the ulcerative colitis patients
by: A. V. Korolev, et al.
Published: (2013-03-01)

Efficacy of mesalazine at ulcerative colitis with nutritional failure
by: A. V. Korolyov, et al.
Published: (2015-03-01)

The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
by: Ohtaki Yuichiro, et al.
Published: (2022-08-01)

Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction
by: Geert D'Haens, et al.
Published: (2023-06-01)

Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease
by: C. J. J. Mulder, et al.
Published: (1998-01-01)

Repurposing Artrestan (Sacubitril/Valsartan), unveiling its anti-inflammatory and fibrinolytic properties in ulcerative colitis in rats
by: Khatereh Kharazmi, et al.
Published: (2025-10-01)

Clinical efficacy study of Qingre Huashi Yuyang formula combined with mesalazine entericcoated tablets in the treatment of damp-heat ulcerative colitis of large intestine: a randomized clinical trial
by: Hu Xiaojuan, et al.
Published: (2024-10-01)

Mesalazine–PAMAM Nanoparticles for Transporter-Independent Intracellular Drug Delivery: Cellular Uptake and Anti-Inflammatory Activity
by: Gorzkiewicz M, et al.
Published: (2023-04-01)

A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis
by: Gionata Fiorino, et al.
Published: (2019-05-01)

Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy–Access to Rapid Treatment (iSTART) approach
by: Silvio Danese, et al.
Published: (2018-10-01)

Mesalazine: a novel therapeutic agent for periodontitis via regulation of periodontal microbiota and inhibiting Porphyromonas gingivalis
by: Yuqi Wang, et al.
Published: (2025-01-01)